Quarterly report pursuant to Section 13 or 15(d)

Deferred Research And Development Arrangements (Details)

v3.7.0.1
Deferred Research And Development Arrangements (Details) - USD ($)
 3 Months Ended 12 Months Ended
Mar. 31, 2017
Mar. 31, 2016
Dec. 31, 2003
Dec. 31, 2016
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Deferred Research and Development Arrangement $ 431,250     $ 450,000
Rexgene Biotech Co., Ltd. [Member]        
Research and Development Arrangement, Contract to Perform for Others [Line Items]        
Research and development arrangement, one-time fee     $ 1,500,000  
Reduction of research and development expenses $ 18,750 $ 18,750    
Research and development period 20 years      
Deferred Research and Development Arrangement $ 431,250     $ 450,000
Royalties paid, percentage of net sales 3.00%